Literature DB >> 20479395

Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.

Gianluigi Ferretti, Alessandra Fabi, Alessandra Felici, Paola Papaldo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20479395     DOI： 10.1200/JCO.2010.28.2525

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.

Authors:  Rena Callahan; Sara Hurvitz
Journal:  Curr Opin Obstet Gynecol       Date:  2011-02       Impact factor: 1.927

Review 2.  Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer.

Authors:  Sara A Hurvitz; Reva Kakkar
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-04-03

3.  Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients.

Authors:  Phillip Kim; Xinjun Liu; Tani Lee; Limin Liu; Robert Barham; Richard Kirkland; Glen Leesman; Anne Kuller; Belen Ybarrondo; Shi-Chung Ng; Sharat Singh
Journal:  Proteome Sci       Date:  2011-12-15       Impact factor: 2.480

4.  Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.

Authors:  Volkan Beylergil; Patrick G Morris; Peter M Smith-Jones; Shanu Modi; David Solit; Clifford A Hudis; Yang Lu; Joseph O'Donoghue; Serge K Lyashchenko; Jorge A Carrasquillo; Steven M Larson; Timothy J Akhurst
Journal:  Nucl Med Commun       Date:  2013-12       Impact factor: 1.690

Review 5.  Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer.

Authors:  Rena Callahan
Journal:  J Adv Pract Oncol       Date:  2014-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.